Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY27 results · Apr–Jun 2026
Lincoln Pharmaceuticals reported revenue from operations of ₹177.28 crore (up 15.1% from Q1 FY26) and net profit of ₹36.23 crore (up 30.9% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 177.28 | 154.07 | +15.1% | 187.28 | −5.3% |
| Other income | 24.26 | 15.27 | +58.9% | (4.20) | Turned profit |
| Total income | 201.55 | 169.34 | +19.0% | 183.08 | +10.1% |
| Profit before tax | 47.55 | 35.39 | +34.4% | 16.70 | +184.7% |
| Net profit for the period | 36.23 | 27.68 | +30.9% | 11.63 | +211.4% |
| EPS, basic (₹) | 18.09 | 13.82 | +30.9% | 5.81 | +211.4% |
| Net margin (%) | 20.4 | 18.0 | 6.2 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 177.28 | 154.07 | +15.1% | 187.28 | −5.3% |
| Other income | 24.26 | 15.27 | +58.9% | (4.20) | Turned profit |
| Total income | 201.55 | 169.34 | +19.0% | 183.08 | +10.1% |
| Profit before tax | 47.55 | 35.39 | +34.4% | 16.70 | +184.7% |
| Net profit for the period | 36.23 | 27.68 | +30.9% | 11.63 | +211.4% |
| EPS, basic (₹) | 18.09 | 13.82 | +30.9% | 5.81 | +211.4% |
| Net margin (%) | 20.4 | 18.0 | 6.2 |
Consolidated
- Filed with BSE
- 13 Aug 2026, 15:14 IST
- Board meeting
- 13 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2026, 15:14 IST
- Board meeting
- 13 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE